Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Michael M. Shen"'
Autor:
Cory Abate-Shen, Amir Lankarani, Matteo Di Bernardo, Michael M. Shen, Rivka L. Shoulson, Soonbum Park, Lijie Rong, Tomasz Owczarek, Talal Syed, Hikmat Al-Ahmadie, David B. Solit, James M. McKiernan, Chee-Wai Chua, Prithi Chakrapani, Jaime Y. Kim
Publikováno v:
Cancer Res
To study the progression of bladder cancer from non–muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches to achieve gene recombination in specific cell populations in the bladder urotheliu
Publikováno v:
Cancer Research. 80:4805-4814
NKX3.1 is the most commonly deleted gene in prostate cancer and is a gatekeeper suppressor. NKX3.1 is haploinsufficient, and pathogenic reduction in protein levels may result from genetic loss, decreased transcription, and increased protein degradati
Autor:
Eric J. Small, Charles L. Sawyers, David W. Goodrich, Richard M. White, Toby T. Hecht, Timothy C. Thompson, Rosalie C. Sears, John K. Lee, Amina Zoubeidi, William L. Dahut, Massimo Loda, Andrew M. Hruszkewycz, Tamara L. Lotan, Daniel W. Lin, Jeffrey Hildesheim, Mark A. Rubin, Jennifer S. Isaacs, Julia T. Arnold, Maria Diaz Meco, Peter S. Nelson, Charles M. Rudin, Himisha Beltran, David R. Rowley, Adam P. Dicker, Max S. Wicha, James L. Gulley, Howard I. Scher, Abdul Tawab-Amiri, Karen E. Knudsen, Michael M. Shen, Evan Y. Yu, Kathleen Kelly
Publikováno v:
Clin Cancer Res
Lineage plasticity has emerged as an important mechanism of treatment resistance in prostate cancer. Treatment-refractory prostate cancers are increasingly associated with loss of luminal prostate markers, and in many cases induction of developmental
Autor:
Anna Dubrovska, Lichun Ma, Wei Guo, Dean G. Tang, J. Joseph Melenhorst, Justin D. Lathia, Sonam Bhatia, Jennifer Cable, Panagiotis Karras, Lei Zhou, Wolf R Wiedemeyer, Xin Wei Wang, Shaheen Sikandar, Junfang Ji, Markus Grompe, Duanqing Pei, Y Rebecca Chin, Chunzhang Yang, Klaus H. Kaestner, Ning Zhang, Richard M. White, Lola M. Reid, Clemens A. Schmitt, Michael M. Shen, Calvin J. Kuo, Erwei Song, Stephanie Ma, Irene Oi-Lin Ng, Carmen Chak-Lui Wong, Irving L. Weissman
Publikováno v:
Ann N Y Acad Sci
The test for the cancer stem cell (CSC) hypothesis is to find a target expressed on all, and only CSCs in a patient tumor, then eliminate all cells with that target that eliminates the cancer. That test has not yet been achieved, but CSC diagnostics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c36522b09379b775b580345f80ee5e
https://europepmc.org/articles/PMC9153245/
https://europepmc.org/articles/PMC9153245/
Autor:
Johann S. de Bono, Pasquale Rescigno, Suzanne Carreira, Gemma Fowler, Penelope Flohr, Christina Guo, Mateus Crespo, Andrea Alimonti, Alessandro Vasciaveo, Jian Ning, Bora Gurel, Beshara Sheehan, Jonathan Welti, Semini Sumanasuriya, Alec Paschalis, Lorenzo Buroni, Abdullah Alajati, Ana Ferreira, Susana Miranda, Claudia Bertan, George Seed, Rita de Cássia Pereira, Paul Workman, Rossitza Christova, Diletta Bianchini, Wei Yuan, Matthew Clarke, Andrea Califano, Gunther Boysen, Antje Neeb, Maryou B K Lambros, Adam Sharp, David Dolling, Nina Tunariu, Michael M. Shen, Daniela Brina, Ines Figueiredo, Amanda Swain, Ruth Riisnaes, Jan Rekowski, Caterina Aversa, Martina Troiani, Mariantonietta D'Ambrosio, Veronica Gil
Publikováno v:
Cancer Res
It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that membranous HER3 protein is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d5013ff02359d2e158e35ab4c349d9
https://europepmc.org/articles/PMC8932336/
https://europepmc.org/articles/PMC8932336/
Autor:
Michael M. Shen, Laura Crowley
Publikováno v:
Cancer Lett
The recent advent of single-cell RNA-sequencing technology has provided new fundamental insights into the heterogeneity of the prostate epithelium. Several independent studies have described extensive heterogeneity of the luminal epithelial compartme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a07d4bdf27677c58f50cd1e0286d52ef
https://europepmc.org/articles/PMC8629925/
https://europepmc.org/articles/PMC8629925/
Autor:
Michael M. Shen, Weiping Li
Publikováno v:
Semin Cancer Biol
Although prostate adenocarcinoma lacks distinguishable histopathological subtypes, prostate cancer displays significant inter- and intratumor heterogeneity at the molecular level and with respect to disease prognosis and treatment response. In princi
Autor:
Teresa A. Milner, Cory Abate-Shen, Antonio Rodriguez-Calero, Sukanya Panja, Michael M. Shen, Renu K. Virk, James M. McKiernan, Elvis A. Maliza, Sven Wenske, Alanna B. Williams, Mark A. Rubin, Aditya Dutta, Hanina Hibshoosh, Vinson Wang, Alexandros Papachristodoulou, Antonina Mitrofanova, Joseph M. Caputo, Matteo Di Bernardo, Jaime Y. Kim, Luis A. Pina Martina, Elizabeth Margolskee, Christopher R. Haas, Guarionex Joel De Castro
Mitochondria provide the first line of defense against the tumor-promoting effects of oxidative stress. Here we show that the prostate-specific homeoprotein NKX3.1 suppresses prostate cancer initiation by protecting mitochondria from oxidative stress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e897d531e7a14db01716d86d2e5e4a8
Autor:
Hanina Hibshoosh, Raul Rabadan, Maho Shibata, Weiping Li, Michael M. Shen, Francesco Cambuli, Shouhong Xuan, Laura Crowley, Brian D. Robinson, Massimo Loda, Luis Aparicio
Publikováno v:
eLife
eLife, Vol 9 (2020)
eLife, Vol 9 (2020)
SummaryUnderstanding the cellular constituents of the prostate is essential for identifying the cell of origin for benign prostatic hyperplasia and prostate adenocarcinoma. Here we describe a comprehensive single-cell atlas of the adult mouse prostat
Autor:
Jelani C. Zarif, Ran Reshef, Aleksandar Obradovic, Rodney Macedo, Alexandros Papachristodoulou, Michael C. Haffner, Pawel Muranski, Tiezheng Yuan, Laura Crowley, Charles G. Drake, Uri Laserson, Michael M. Shen, Zoila A. Lopez-Bujanda, Thomas R. Nirschl, H. Benjamin Larman, Mithil Soni, Timothy O'Donnell, Emmanuel S. Antonarakis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundProstate cancer is the second leading cause of cancer-related death in men in the USA; death occurs when patients progress to metastatic castration-resistant prostate cancer (CRPC). Although immunotherapy with the Food and Drug Administrati